Egypt's Eva Pharma to export COVID-19 drug remdesivir to India

The drug targets moderate to severe cases of COVID-19

  
Lab technicians work on investigational coronavirus disease (COVID-19) treatment drug "Remdesivir" June 25, 2020.

Lab technicians work on investigational coronavirus disease (COVID-19) treatment drug "Remdesivir" June 25, 2020.

REUTERS/Amr Abdallah Dalsh

CAIRO- Egypt's Eva Pharma on Monday signed an agreement to provide India with 300,000 doses of remdesivir, used in the treatment of COVID-19, the company said in a statement.

The agreement, which was signed at the Indian embassy in Cairo, is aimed at helping India combat a surge in infections which has overwhelmed the health system and held close to record daily highs on Monday. 

Eva Pharma, a generic drugmaker established in 1997, said in June 2020 it had received a licence from Gilead Sciences Inc to make remdesivir in Egypt and distribute it in 127 countries.

The drug targets moderate to severe cases of COVID-19 in intensive care who require oxygen.

Eva Pharma didn't disclose the deal's value.

(Reporting by Ehab Farouk; Writing by Mahmoud Mourad; Editing by Nick Macfie) ((mahmoud.mourad@thomsonreuters.com;))

More From North Africa